Harnessing multimodal data integration to advance precision oncology
Advances in quantitative biomarker development have accelerated new forms of data-driven
insights for patients with cancer. However, most approaches are limited to a single mode of …
insights for patients with cancer. However, most approaches are limited to a single mode of …
[HTML][HTML] Anticancer drug resistance: An update and perspective
R Nussinov, CJ Tsai, H Jang - Drug Resistance Updates, 2021 - Elsevier
Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …
can inhibit the action of the mutant protein; however, drug resistance almost invariably …
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
CA Milbury, J Creeden, WK Yip, DL Smith, V Pattani… - PLoS …, 2022 - journals.plos.org
FoundationOne® CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-
approved companion diagnostic test to identify patients who may benefit from treatment in …
approved companion diagnostic test to identify patients who may benefit from treatment in …
PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects
Breast cancer is a serious health problem worldwide, representing the second cause of
death through malignancies among women in developed countries. Population …
death through malignancies among women in developed countries. Population …
PI3K inhibitors are finally coming of age
Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …
one of the most frequently dysregulated signaling pathways observed in cancer patients that …
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
A variety of targeted anticancer agents have been successfully introduced into clinical
practice, largely reflecting their ability to inhibit specific molecular alterations that are …
practice, largely reflecting their ability to inhibit specific molecular alterations that are …
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
N Vasan, LC Cantley - Nature Reviews Clinical Oncology, 2022 - nature.com
Numerous agents targeting various phosphatidylinositol 3-kinase (PI3K) pathway
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
O Martínez-Sáez, N Chic, T Pascual, B Adamo… - Breast cancer …, 2020 - Springer
Abstract Purpose The therascreen PIK3CA mutation assay and the alpha-specific PI3K
inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced …
inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced …
Cancer driver mutations: predictions and reality
D Ostroverkhova, TM Przytycka… - Trends in Molecular …, 2023 - cell.com
Cancer cells accumulate many genetic alterations throughout their lifetime, but only a few of
them drive cancer progression, termed driver mutations. Driver mutations may vary between …
them drive cancer progression, termed driver mutations. Driver mutations may vary between …